EUVIMEDEUVIMED entdecken
Crossref

Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis

Okechukwu Valentine Nwogbo iD, Hong Fang, Wei Wang, Jie Xu, Roberto N Miranda iD, Prithviraj Bose, Chi Young Ok, Jeffrey L Jorgensen, L Jeffrey Medeiros, Sa A Wang

American Journal of Clinical Pathology · 2024

DOI: 10.1093/ajcp/aqad187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Okechukwu Valentine Nwogbo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pathology & Laboratory Medicine Division, University of Texas MD Anderson Cancer Center, Houston, TX, US. Hauptthemen laut MEDLINE: Immunophenotyping, Mastocytosis, Systemic, Flow Cytometry, Mast Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Flow cytometric immunophenotyping (FCI) is a fast and sensitive method for characterizing hematolymphoid neoplasms. It is not widely used in the workup of systemic mastocytosis (SM), in part because of the technical challenges and in part because the utility of FCI in assessing mast cells is not well understood. The objectives of this study were to assess the diagnostic utility of FCI in establishing a diagnosis of SM and distinguishing SM from nonneoplastic mast cells and to examine the immunophenotypic findings among SM subtypes.

Methods

We performed FCI on bone marrow samples suspicious for SM using a panel consisting of CD2, CD25, CD30, CD45, CD117, and HLA-DR.

Results

The cohort included 88 SM cases: 67 without an associated hematologic neoplasm (AHN) (PureSM) and 21 with an AHN (SM-AHN). We also assessed 40 normal/reactive controls. Overall, FCI was adequate for interpretation in 87 of 88 (99%) cases and detected at least 1 immunophenotypic aberrancy in 100% of SM cases. CD2, CD25, and CD30 were positive in 78%, 98%, and 90% of SM cases vs 0%, 13%, and 13% of cases with normal/reactive mast cells (P < .0001 for all). Two or 3 abnormalities were observed in 92% of SM cases but not in normal/reactive mast cells. Among SM cases, SM-AHN showed statistically significant less CD2 (38% vs 91%, P < .0001) and less co-expression of all 3 aberrant markers (CD2, CD25, and CD30 positive in 38% vs 86% of cases; P < .0001) than PureSM. Immunohistochemical analysis showed consistently weaker or focal expression of CD2, CD25, and CD30 than FCI, with CD2 and CD30 being falsely negative in 40% and 50% cases, respectively. A KIT D816V mutation was detected in 67% of PureSM cases and 76% of SM-AHN cases.

Conclusions

Flow cytometric immunophenotyping is a quick, sensitive, high-yield tool for evaluating the immunophenotype of mast cells. An abnormal FCI finding should prompt careful histologic evaluation and sensitive KIT D816V mutation testing to address the possibility of SM. CD2, CD25, and CD30 are important markers for the detection of immunophenotypic aberrancy of mast cells, and their frequencies of aberrancy differ across SM subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunophenotypingMastocytosis, SystemicFlow CytometryMast CellsHumansMiddle AgedFemaleMaleAdultAgedSensitivity and SpecificityAged, 80 and overYoung AdultAdolescent

Stichwörter der Autor:innen

KIT mutationSM-AHNimmunohistochemistrymulticolor flow cytometryreactive mast cellssystemic mastocytosis (SM)

Autor:innen und Institutionen

  • Pathology & Laboratory Medicine Division, University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, US.

ORCID-Profile: Okechukwu Valentine Nwogbo, Roberto N Miranda

Zitieren

APA

Nwogbo, O. V., Fang, H., Wang, W., Xu, J., Miranda, R. N., Bose, P., Ok, C. Y., Jorgensen, J. L., Medeiros, L. J., & Wang, S. A. (2024). Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad187

Vancouver

Nwogbo OV, Fang H, Wang W, Xu J, Miranda RN, Bose P, et al. Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad187

BibTeX
@article{Nwogbo2024,
  author = {Nwogbo, Okechukwu Valentine and Fang, Hong and Wang, Wei and Xu, Jie and Miranda, Roberto N and Bose, Prithviraj and Ok, Chi Young and Jorgensen, Jeffrey L and Medeiros, L Jeffrey and Wang, Sa A},
  title = {Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis},
  journal = {American Journal of Clinical Pathology},
  year = {2024},
  doi = {10.1093/ajcp/aqad187}
}
Kostenlos starten →